Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will now oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical juncture for the company as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study. Annovis indicated that Fang will play a key role in leading scientific strategy through upcoming clinical and regulatory milestones, including a subsequent New Drug Application submission.
According to the company, Fang has been instrumental in advancing its clinical development efforts since joining. His elevation to CSO reflects the company’s commitment to strengthening its leadership team as it approaches key inflection points. Buntanetap, an investigational once-daily oral therapy, inhibits the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
For more details on the promotion, visit the full press release. Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead drug candidate, buntanetap (formerly posiphen), is designed to target multiple neurotoxic proteins simultaneously.
The appointment of Fang as CSO is expected to provide continuity and scientific leadership as Annovis navigates the complexities of late-stage clinical trials and regulatory submissions. The company’s focus on biomarkers and translational science could enhance the probability of success in its Alzheimer’s program, which is closely watched by investors and researchers alike.
For ongoing updates on Annovis Bio, visit the company’s newsroom at https://ibn.fm/ANVS. More information about Annovis is available at www.annovisbio.com.
